semaglutide efficacy weight loss Day 2: Wegovy (Semaglutide 2.4 mg weekly injection) Class: GLP-1 receptor agonist Avg Loss: ~15% of baseline weight Dosing: Weekly subcutaneous injection FDA Approved: June 2021 for chronic weight management Pros Side-by-side efficacy of weight loss

According to the National Family Health Survey (NFHS-5) 2019-21, obesity is increasing, with 6.5% of Indian adults classified as obese

However, subtle metabolic dysregulation can persist for 8 to 12 weeks, making calorie control difficult during this extended window

Step 1: check the temperature What was the ambient temperature where the pen was sitting

Treatment recommendations are based on each patients health history, goals, and response to therapy

The drug is being developed by Eli Lilly and Company, which has announced plans to progress retatrutide into Phase 3 clinical trials across multiple indications, including obesity, type 2 diabetes, and liver disease

PMID: 30903796